Quick Answer
– The valsartan lawsuit centers on NDMA contamination in blood pressure medication, with cases consolidated under MDL 2875 in the District of New Jersey.
– Claimants who took contaminated valsartan and were later diagnosed with specific cancers may qualify for compensation, including those whose cases remain unresolved in 2026.
– Payout estimates for individual personal injury claims range from $50,000 to over $300,000 depending on cancer type, severity, exposure duration, and defendant-specific settlement terms.
Case Snapshot
| Detail | Information |
|---|---|
| Court | U.S. District Court, District of New Jersey |
| MDL Number | MDL 2875 — In re: Valsartan, Losartan, and Irbesartan Products Liability Litigation |
| Assigned Judge | Hon. Robert B. Kugler |
| Special Master | Hon. Thomas I. Vanaskie (ret.) |
| Initial Consolidation Date | February 14, 2019 |
| Primary Contamination | NDMA (N-nitrosodimethylamine), a probable human carcinogen |
| Status (2026) | Individual tort claims ongoing; multiple defendant settlements concluded; remaining defendants in active litigation |
| Total Claims Filed | Over 1,000 personal injury cases active in MDL as of early 2026 |
| Settlement Fund | Undisclosed aggregate; defendant-specific settlement amounts vary |
The valsartan lawsuit is one of the largest pharmaceutical mass tort proceedings in the country, built on evidence that contaminated blood pressure drugs exposed hundreds of thousands of patients to a known carcinogen for years. Multiple major defendants have now reached settlements. Others continue to litigate. For claimants still holding unresolved cases in 2026, the procedural landscape has changed significantly since the early MDL years.
Contaminated valsartan flooded the U.S. market beginning as early as 2012. The FDA did not initiate its first recall until July 2018. That gap in regulatory response is central to the plaintiffs' case.
The litigation spans cancer diagnoses, economic losses, and medical monitoring claims. MDL 2875 has processed bellwether trials, large-scale defendant settlements, and ongoing individual case resolutions.
Understanding what the lawsuit looks like in 2026 requires knowing which defendants have settled, which have not, and where unresolved claimants stand procedurally.
Valsartan Lawsuit Update 2026: Where the Case Stands Right Now
The valsartan lawsuit in 2026 is no longer in its early consolidation phase. It is in the resolution and remaining-defendant litigation phase.
MDL 2875 remains open in the District of New Jersey under Judge Robert B. Kugler. Several major manufacturing defendants have reached confidential or disclosed settlements. Individual personal injury cases that did not resolve in earlier settlement rounds are now proceeding through case-specific workup, discovery, and negotiation.
The court has moved cases involving primary manufacturer Zhejiang Huahai Pharmaceutical (ZHP) through substantial settlement negotiations. Cases against certain U.S.-based distributors and finished-dose manufacturers have followed different resolution timelines.
Key 2026 Procedural Facts:
- MDL 2875 remains active for personal injury claims
- Bellwether trials informed settlement valuations for multiple defendant groups
- Plaintiffs who did not accept prior settlement offers remain in active case management
- The court continues to enforce Plaintiff Fact Sheet compliance deadlines
*Attorneys handling these claims point to the court's continued pressure on both sides to resolve individual cases efficiently, with case-specific factors now carrying more weight in valuation than early settlement matrices did.*
Valsartan Lawsuit Payout: What Compensation Numbers Look Like
Valsartan lawsuit payouts vary considerably based on cancer diagnosis, disease severity, duration of medication exposure, and which defendant is responsible for the specific contaminated product.
There is no single uniform payout. Settlement structures for mass tort pharmaceutical cases like MDL 2875 typically use tiered compensation grids that assign higher values to more severe or terminal diagnoses.
Estimated Payout Ranges (Individual Personal Injury Claims):
| Cancer Type / Severity | Estimated Compensation Range |
|---|---|
| Diagnosed cancer, full remission | $50,000 to $125,000 |
| Diagnosed cancer, ongoing treatment | $100,000 to $225,000 |
| Diagnosed cancer, advanced stage | $175,000 to $300,000+ |
| Wrongful death (cancer caused fatality) | $250,000 to $500,000+ |
| Economic loss / medical monitoring only | $5,000 to $25,000 |
These figures reflect plaintiff-side estimates and comparable MDL settlement structures. Individual results depend on specific defendant settlement terms and case facts.
*Attorneys handling these claims point to duration of valsartan use as a critical multiplier — claimants who took contaminated medication for three or more years typically receive higher valuations than short-term users.*
Valsartan Lawsuit Settlement Amounts by Defendant
Settlement amounts in the valsartan litigation are defendant-specific, not consolidated into one global fund. Each manufacturer and distributor negotiated separately.
Zhejiang Huahai Pharmaceutical (ZHP), the Chinese API manufacturer identified as the primary source of NDMA contamination, reached settlement agreements covering a substantial portion of personal injury plaintiffs. Specific aggregate amounts were not publicly disclosed under settlement terms, consistent with confidential mass tort resolutions.
Hetero Labs and Aurobindo Pharma, two India-based generic manufacturers named in MDL 2875, reached separate settlement arrangements with qualifying plaintiffs. Terms were similarly confidential.
Torrent Pharmaceuticals faced significant plaintiff pressure after bellwether discovery revealed contamination timelines. Settlement posture for Torrent-linked claims has evolved through 2025 into 2026.
Key Settlement Architecture Facts:
- Settlements are defendant-specific, not global
- Plaintiffs must release claims against specific defendants upon accepting payment
- Claims against non-settling defendants proceed independently
- Settlement fund amounts remain confidential per agreement terms
*Attorneys handling these claims point to the importance of identifying which manufacturer produced the specific valsartan lot a claimant ingested — this determines which defendant's settlement fund a claim draws from.*
Litigation Watch: MDL 2875 is not a single settlement pool. Each defendant negotiated separately, and unresolved claims against non-settling defendants remain in active litigation as of 2026.
Valsartan Cancer Lawsuit Eligibility: The Core Requirements
A claimant is eligible to pursue a valsartan lawsuit if they took a recalled lot of valsartan-containing medication and subsequently received a cancer diagnosis consistent with NDMA exposure.
Eligibility rests on three core elements: documented medication use, a qualifying cancer diagnosis, and a causal connection the plaintiff can support with medical records and pharmacy fill history.
Core Eligibility Requirements:
- Took valsartan, valsartan/HCTZ, or another ARB product manufactured by a recalled defendant
- Prescription filled between approximately 2012 and 2018 (the contamination window identified by FDA)
- Diagnosed with a qualifying cancer (see next section) after a reasonable latency period
- Cancer diagnosis supported by pathology records
- Pharmacy records or prescription documentation available to confirm medication source
*Attorneys handling these claims point to pharmacy fill records as the single most important piece of initial documentation — without confirmed lot information or manufacturer identification, connecting the claimant to a specific defendant is substantially harder.*
Quick-Facts Box: What Disqualifies a Claim
- Cancer diagnosed before valsartan use began
- Valsartan prescription from a non-recalled manufacturer or lot
- No supporting medical documentation of diagnosis
- Statute of limitations already expired with no tolling protection
Valsartan Lawsuit: Which Cancers Qualify for a Claim
The cancers most directly linked to NDMA exposure are the primary qualifying diagnoses in MDL 2875 personal injury claims.
NDMA is classified by the International Agency for Research on Cancer (IARC) as a Group 2A probable human carcinogen. Animal studies and occupational exposure data informed the specific cancer categories plaintiffs have pursued.
Qualifying Cancer Diagnoses:
| Cancer Type | Notes |
|---|---|
| Hepatocellular carcinoma (liver cancer) | Primary NDMA target organ; strongest scientific link |
| Colorectal cancer | Frequently litigated; large plaintiff volume |
| Gastric cancer (stomach cancer) | Supported by NDMA exposure data |
| Esophageal cancer | Named in plaintiff fact sheets |
| Non-Hodgkin's lymphoma | Included in multiple defendant settlement eligibility lists |
| Bladder cancer | Qualifying diagnosis in most defendant-specific grids |
| Kidney cancer (renal cell carcinoma) | Recognized in MDL plaintiff fact sheet categories |
Diagnoses not on this list do not automatically disqualify a claimant. Case-specific expert testimony may support a broader theory of causation.
*Attorneys handling these claims point to liver cancer as consistently commanding the highest settlement valuations, given the directness of the NDMA-hepatocellular carcinoma scientific connection.*
Valsartan MDL 2875 Update 2026: Court Proceedings and Current Posture
MDL 2875, formally captioned *In re: Valsartan, Losartan, and Irbesartan Products Liability Litigation*, is assigned to Judge Robert B. Kugler in the U.S. District Court for the District of New Jersey, Camden Division.
The MDL was established by the Judicial Panel on Multidistrict Litigation in February 2019. By late 2020, it encompassed over 1,000 active personal injury cases alongside economic loss and medical monitoring claims.
2025-2026 Court Posture:
- Bellwether personal injury trials were scheduled and their preparations informed defendant settlement calculations
- The court has issued case management orders requiring plaintiff fact sheet updates from remaining active plaintiffs
- Judge Kugler's court has enforced dismissal for plaintiffs who failed to meet documentation compliance deadlines
- Cases against defendants who have not settled continue through individual case-specific workup
The MDL also includes a separate class of economic loss plaintiffs — people who paid for contaminated valsartan but did not develop cancer. These claims have followed a distinct litigation track with different settlement considerations.
*Attorneys handling these claims point to the MDL's document compliance requirements as a decisive factor — claimants whose attorneys miss fact sheet deadlines face dismissal regardless of the underlying merit of their claim.*
Litigation Watch: Judge Kugler's court has actively dismissed cases for documentation failures, making attorney compliance with MDL case management orders as critical as the underlying medicine in these claims.
Valsartan Lawsuit Defendants That Have Settled
Several major defendants in MDL 2875 reached settlement agreements with personal injury plaintiffs. These resolutions concluded claims against specific manufacturers within the MDL framework.
Defendants With Concluded or Substantially Completed Settlements:
| Defendant | Role | Settlement Status |
|---|---|---|
| Zhejiang Huahai Pharmaceutical (ZHP) | API manufacturer; primary NDMA source | Settlement reached; terms confidential |
| Hetero Labs | Generic finished-dose manufacturer | Settlement reached; claims largely resolved |
| Aurobindo Pharma | Generic finished-dose manufacturer | Settlement reached; terms confidential |
| Mylan N.V. | U.S. distributor / finished-dose manufacturer | Settlement negotiations substantially concluded |
| Major Pharmaceuticals / Solco Healthcare | U.S.-based distributors | Settlement resolutions progressed through 2025 |
Acceptance of settlement from one defendant does not foreclose claims against other defendants in the same supply chain unless the plaintiff expressly releases all parties.
*Attorneys handling these claims point to the importance of reviewing any settlement release language carefully before signing — broad releases have been used in pharmaceutical MDLs to extinguish claims a plaintiff did not intend to surrender.*
Valsartan Lawsuit Remaining Defendants: Who Is Still Litigating
Not every defendant in MDL 2875 has settled. Certain manufacturers and distributors continue to contest liability as of 2026.
Torrent Pharmaceuticals remains one of the more actively litigated defendants. Torrent's contamination timeline and internal quality control decisions were subjects of significant bellwether discovery. Settlement talks with Torrent-linked plaintiffs have continued without reaching a globally concluded resolution as of early 2026.
Teva Pharmaceuticals faced separate contamination allegations tied to its own manufacturing processes. Teva's litigation posture has involved both settlement discussions and contested motions on causation expert admissibility.
Current Active Litigation Points:
- Causation experts remain contested in several defendant-specific tracks
- Daubert challenges to NDMA-cancer causation science have been litigated and largely resolved in plaintiffs' favor at the MDL level
- Remaining defendants are engaging in individual case-specific discovery for bellwether selection
- Some defendants are pursuing state court remand motions for specific cases
*Attorneys handling these claims point to the Daubert rulings on causation as a significant plaintiff-side development — the court's rejection of manufacturer challenges to NDMA-cancer science has strengthened the overall litigation posture for unresolved claimants.*
Litigation Watch: Torrent Pharmaceuticals and Teva remain in active contested litigation as of 2026, making cases tied to those manufacturers' products still viable for claimants who have not yet settled.
Valsartan NDMA Contamination: How the Lawsuit Was Built
The valsartan lawsuit exists because of a manufacturing defect invisible to patients and, for years, to regulators. NDMA entered the valsartan supply chain through a process change at ZHP's manufacturing facility in Linhai, China.
ZHP changed its synthesis process for valsartan's active pharmaceutical ingredient (API) around 2012. The new process created a chemical reaction that produced NDMA as a byproduct. The company did not detect the contamination for years. The FDA did not identify it until a European regulatory agency (EMA) flagged the issue in 2018.
Contamination Timeline:
| Date | Event |
|---|---|
| ~2012 | ZHP changes API synthesis process; NDMA contamination begins |
| June 2018 | European Medicines Agency flags NDMA contamination |
| July 2018 | FDA issues first valsartan recall |
| August 2018 | Additional manufacturers recalled; contamination scope widens |
| February 2019 | MDL 2875 established in D.N.J. |
| 2020-2022 | Bellwether discovery and expert disclosure phases |
| 2023-2025 | Defendant-specific settlements reached |
| 2026 | Remaining defendant litigation and individual case resolution ongoing |
NDMA at the levels found in contaminated valsartan products exceeded FDA interim acceptable daily intake limits by factors of up to 17 times in some tested lots.
*Attorneys handling these claims point to the 2012-to-2018 exposure window as the central factual core of every case — claimants who can document prescription fills within that period have the strongest foundation for their claims.*
Valsartan Class Action vs. Mass Tort: What the Difference Means for You
The valsartan litigation is a mass tort, not a traditional class action, and that distinction directly affects how compensation is calculated and paid.
In a class action, all plaintiffs share a common settlement fund divided by formula, regardless of individual injury severity. A mass tort preserves each plaintiff's individual claim and calculates compensation based on that specific plaintiff's diagnosis, medical history, and damages.
Side-by-Side Comparison:
| Feature | Class Action | Mass Tort (MDL 2875) |
|---|---|---|
| Individual compensation | Shared pool, small per-person payment | Individual valuation per plaintiff |
| Cancer diagnosis required | Not necessarily | Required for personal injury claim |
| How cases proceed | Single trial resolves all | Individual claims, coordinated discovery |
| Settlement negotiation | Class-wide | Defendant-specific, plaintiff-specific |
| Opt-out rights | Yes, within deadline | Every plaintiff independently represented |
The economic loss and medical monitoring tracks within MDL 2875 function more like class-style resolution. Personal injury claims are fully individualized.
*Attorneys handling these claims point to the mass tort structure as financially significant for cancer claimants — it means a plaintiff with hepatocellular carcinoma is not sharing a fund with thousands of others who only paid for contaminated pills but never got sick.*
Valsartan Recall Lawsuit: Who Qualifies to File in 2026
A person qualifies to file a valsartan lawsuit in 2026 if they have not previously settled or dismissed their claim, and if they meet the eligibility criteria tied to medication use and cancer diagnosis.
New claimants may still be eligible if their statute of limitations has not expired and if they can document the medication and diagnosis. This is a case-specific determination.
2026 Qualification Checklist:
- Took recalled valsartan between 2012 and 2018
- Manufacturer or distributor was a named MDL 2875 defendant
- Diagnosed with a qualifying cancer (liver, colorectal, gastric, esophageal, lymphoma, bladder, or kidney)
- Cancer diagnosis occurred after the start of valsartan use
- Statute of limitations has not run in your state (see section below)
- Medical records and pharmacy documentation are obtainable
Who Does Not Qualify in 2026:
- Claimants who already settled and signed a release of claims
- Claimants whose cases were dismissed with prejudice for failure to comply with court orders
- Claimants whose state statute of limitations has expired without applicable tolling
*Attorneys handling these claims point to the availability of pharmacy records subpoenas as a tool for claimants who no longer have their prescription records — pharmacies are typically required to retain dispensing records for 5 to 10 years depending on state law.*
Litigation Watch: Eligibility in 2026 is a real possibility for claimants who have not previously resolved their claims, but only if their statute of limitations remains open — an attorney's review is needed to confirm this on a state-by-state basis.
Valsartan Lawsuit Filing Deadline 2026: Statute and Tolling
The filing deadline for a valsartan lawsuit depends on state-specific statutes of limitations, the discovery rule, and whether any tolling agreement with specific defendants is still operative.
MDL 2875 does not eliminate state-law statutes of limitations. Each state sets its own window — typically two to three years from the date the claimant discovered (or reasonably should have discovered) the connection between their medication and their cancer diagnosis.
Critical Filing Deadline Factors in 2026:
| Factor | Impact on Deadline |
|---|---|
| State statute of limitations | Sets the baseline window (2 to 3 years in most states) |
| Discovery rule | Clock starts when claimant knew or should have known of the injury/cause link |
| Tolling agreements with specific defendants | Paused the clock for some plaintiffs during active settlement negotiations — check current status |
| Fraudulent concealment doctrine | May extend the limitations period if defendant concealed contamination |
| Death of the original claimant | Wrongful death filing deadlines are separately governed by state law |
The FDA's public recall announcements in July and August 2018 are frequently cited as the date general public awareness was established. Courts have used this as a reference point for when the discovery rule clock arguably began running for many plaintiffs.
*Attorneys handling these claims point to 2026 as potentially the last viable filing window for claimants whose discovery clock began at or around the 2018 recall dates — in states with two-year limitations periods, those windows have already closed without tolling protection.*
Valsartan Lawsuit Statute of Limitations: State-by-State Risk
The statute of limitations is the single greatest procedural risk for a valsartan claimant evaluating their options in 2026.
Every state has its own limitations period for pharmaceutical product liability claims. Courts applying the discovery rule begin the clock when a plaintiff knew or reasonably should have known that their cancer may have been caused by a contaminated medication.
State Statute of Limitations Reference Table (Personal Injury / Product Liability):
| State | Limitations Period | Notes |
|---|---|---|
| California | 2 years | Discovery rule applies |
| New York | 3 years | Discovery rule applies |
| Texas | 2 years | Discovery rule applies |
| Florida | 4 years (reduced to 2 years for claims accruing after 3/24/23) | Legislative change affects newer claims |
| Illinois | 2 years | Discovery rule applies |
| Pennsylvania | 2 years | Discovery rule applies |
| Ohio | 2 years | Discovery rule applies |
| New Jersey | 2 years | Discovery rule; MDL home state |
| Georgia | 2 years | Discovery rule applies |
| North Carolina | 3 years | Discovery rule applies |
This table reflects general product liability limitations periods. Individual claim analysis requires attorney review of the specific accrual date.
*Attorneys handling these claims point to the fraudulent concealment doctrine as a potential lifeline in states where the standard limitations period has technically closed — if ZHP or another defendant actively concealed contamination, tolling arguments may extend the filing window.*
How to File a Valsartan Lawsuit Claim in 2026
Filing a valsartan lawsuit in 2026 means retaining a pharmaceutical mass tort attorney, gathering medical and pharmacy documentation, and formally entering the MDL 2875 process through a Short Form Complaint.
The process does not require filing independently in federal court. Plaintiffs join MDL 2875 through a coordinated filing procedure managed by court-approved liaison counsel.
Step-by-Step Filing Process:
- Retain a mass tort attorney experienced in pharmaceutical product liability
- Gather documentation: pharmacy fill records, prescription bottles or labels, manufacturer identification if possible
- Obtain medical records documenting cancer diagnosis, pathology reports, and treatment history
- Attorney files a Short Form Complaint in MDL 2875 in the District of New Jersey
- Complete a Plaintiff Fact Sheet (PFS) — a detailed MDL-specific document required by court order
- Case is assigned to the relevant defendant-specific litigation track
- Individual case discovery proceeds; settlement negotiations follow case valuation
Most pharmaceutical mass tort attorneys handle these cases on contingency — no upfront fee. Attorney fees are paid as a percentage of any recovery.
*Attorneys handling these claims point to the Plaintiff Fact Sheet as a document requiring careful attention — incomplete or inconsistent PFS submissions have led to case dismissals in MDL 2875, and the court has not been lenient in enforcing these requirements.*
Litigation Watch: Filing in 2026 requires both statute-of-limitations viability and strict compliance with MDL 2875 court orders — missing either element can end a claim before it reaches valuation.
Valsartan Lawsuit State-by-State Filing: Where Claims Are Processed
All valsartan personal injury claims in the federal system are processed through MDL 2875 in the District of New Jersey, regardless of where the plaintiff lives or where they were diagnosed.
The MDL centralization means a claimant in Texas, California, or Florida does not file in their home state's federal court. Their case transfers to New Jersey as part of the consolidated proceedings.
How State Geography Affects the Case:
| State-Related Factor | Impact |
|---|---|
| Where the plaintiff files | Initial filing may be in home district, then transferred to MDL |
| Applicable law | Plaintiff's home state law governs limitations periods and some liability rules |
| State court option | Some claims may be filed in state court instead of federal MDL — strategy varies |
| Discovery obligations | MDL court orders govern regardless of home state |
| Settlement distribution | Not state-specific; based on individual case valuation |
Some plaintiffs have pursued claims in state court rather than the federal MDL, particularly where state law offers procedural advantages or where the defendant is domiciled in that state. Attorney strategy determines the optimal venue.
*Attorneys handling these claims point to state court as a viable alternative track in specific circumstances — particularly for claims against defendants domiciled in states with favorable product liability law — but this requires careful jurisdictional analysis.*
What Type of Attorney Handles a Valsartan Lawsuit
A valsartan lawsuit requires a pharmaceutical product liability attorney with specific mass tort MDL experience. This is not a general personal injury case.
The litigation involves complex science (NDMA carcinogenicity), multi-defendant supply chain analysis, federal MDL procedure, and settlement matrix negotiation. Attorneys without pharmaceutical mass tort backgrounds are at a structural disadvantage in this litigation.
Attorney Profile for Valsartan Claims:
| Characteristic | Why It Matters |
|---|---|
| Practice area: pharmaceutical mass tort | MDL procedure and plaintiff fact sheet compliance require specialized knowledge |
| MDL 2875 familiarity | Prior MDL filing experience reduces risk of procedural dismissal |
| Contingency fee basis | Standard in mass tort; no upfront cost to claimant |
| Access to co-counsel networks | Large MDL cases often involve co-counsel arrangements with MDL leadership firms |
| Medical expert relationships | Causation experts for NDMA-related cancers are critical to case valuation |
Law firms that serve on MDL 2875's Plaintiffs' Steering Committee (PSC) have the deepest direct access to discovery, settlement negotiations, and case management orders. Plaintiffs represented by PSC firms or affiliated co-counsel firms operate with an informational advantage.
*Attorneys handling these claims point to MDL Plaintiffs' Steering Committee membership as a proxy for litigation depth — PSC firms have had direct access to defendant discovery and settlement negotiation tables that non-PSC firms have not.*
Frequently Asked Questions
What is the current status of the valsartan lawsuit in 2026?
MDL 2875 remains active in the U.S. District Court for the District of New Jersey under Judge Robert B. Kugler.
Multiple defendants have settled personal injury claims; others including Torrent Pharmaceuticals and Teva remain in active litigation.
Individual cases that were not resolved in prior settlement rounds continue through case-specific workup and negotiation.
How much is a valsartan lawsuit payout worth?
Individual payout estimates range from approximately $50,000 for cancer diagnoses in remission to over $300,000 for advanced-stage cancer cases, with wrongful death claims potentially exceeding $500,000.
Compensation depends on cancer type, disease severity, duration of valsartan use, and which defendant's settlement fund the claim draws from.
Economic loss-only claims (no cancer diagnosis) typically yield significantly smaller amounts in the $5,000 to $25,000 range.
What cancers qualify for a valsartan lawsuit?
The primary qualifying cancers in MDL 2875 are hepatocellular carcinoma (liver cancer), colorectal cancer, gastric cancer, esophageal cancer, non-Hodgkin's lymphoma, bladder cancer, and kidney cancer.
Liver cancer carries the strongest scientific connection to NDMA and typically commands the highest settlement valuations.
Claims involving other cancer types may still be viable depending on case-specific expert support, but these seven are the most consistently recognized qualifying diagnoses.
What is MDL 2875 and how does it affect my claim?
MDL 2875 is the federal multidistrict litigation consolidating valsartan personal injury cases in the District of New Jersey.
It coordinates discovery, expert disclosure, and bellwether proceedings across all federal valsartan claims, regardless of where the plaintiff lives.
Your individual case retains its own identity within MDL 2875 — unlike a class action, compensation is calculated individually, not shared from a single pool.
Is there still a deadline to file a valsartan lawsuit in 2026?
Filing deadlines depend on each state's statute of limitations and the discovery rule — most states allow two to three years from when the claimant knew or should have known of the connection between their medication and their cancer.
For claimants who became aware of the connection around the 2018 FDA recalls, limitations windows in two-year states have likely closed without applicable tolling protection.
An attorney evaluation of the specific accrual date and any tolling arguments is the only way to confirm whether a 2026 filing remains viable.
What type of lawyer handles valsartan lawsuits?
Valsartan claims require a pharmaceutical product liability attorney with direct mass tort MDL experience.
Attorneys affiliated with MDL 2875's Plaintiffs' Steering Committee or co-counsel networks connected to PSC firms have the most direct access to case intelligence, settlement negotiations, and court filings.
Most handle cases on a contingency fee basis — no recovery means no attorney fee.
Closing
The valsartan litigation has moved past its early consolidation phase. Multiple defendants have settled. Others remain contested. For claimants who have not yet resolved their cases, 2026 represents a critical window — one where statute of limitations exposure and MDL compliance requirements are both active threats to claim viability.
The most important immediate step for any person who took recalled valsartan and received a qualifying cancer diagnosis is a case-specific consultation with a pharmaceutical mass tort attorney. This is not a general personal injury matter. The procedural history of MDL 2875 and the remaining litigation posture require counsel with direct MDL experience.
Waiting does not preserve options in this litigation. Statutes of limitations are running, and courts have shown no hesitation dismissing cases that fail procedural requirements.
